MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games

HIV-1

Search medical newsFind research, conditions and clinical updates
  • Home
  • HIV-1
Doravirine and Islatravir Combination Proves Non-Inferior to B/F/TAF: A New Era for Two-Drug HIV Maintenance
Posted inInfectious Diseases news

Doravirine and Islatravir Combination Proves Non-Inferior to B/F/TAF: A New Era for Two-Drug HIV Maintenance

Posted by By MedXY 02/15/2026
Phase 3 trial results demonstrate that a daily fixed-dose combination of doravirine and islatravir effectively maintains virological suppression in adults with HIV-1, offering a comparable and safe alternative to standard integrase inhibitor-based regimens.
Read More

Take a game break

Explore a few games from MedXY.

Explore all games
  • Racial and Ethnic Equity in Pediatric Perioperative Cardiac Arrest Survival: Insights from a Large National Cohort
  • Emerging Plasma Biomarkers in Systemic Sclerosis-Associated Lung Disease: Insights from High-Throughput Proteomics
  • Hepatic Artery Complications After Pediatric Liver Transplantation: Insights from the HEPATIC Registry
  • Topical Sirolimus Gel as a Novel Treatment for Hyperplastic Rosacea: Efficacy, Safety, and Innovative Volume Assessment
  • Preserving Lower Lip Function in Facial Synkinesis: Transitioning from Platysma Myectomy to Myotomy
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top